PF-06260933

SKU: orb1303048

Description

PF-06260933

Research Area

Signal Transduction

Key Properties

• CAS Number: 1811510-56-1
• MW: 296.75
• Purity: 99.63%
• Formula: C₁₆H₁₃ClN₄
• SMILES: Nc1ccc(cn1)-c1cnc(N)c(c1)-c1ccc(Cl)cc1
• Target: MAPK
• Solubility: DMSO:50 mg/mL (168.49 mM);10% DMSO+40% PEG300+5% Tween 80+45% Saline:2 mg/mL (6.74 mM)

Bioactivity

• Target IC50:
  MAP4K4:3.7 nM
• In Vivo:
  Treatment with PF-06260933 does not modify plasma lipid content in a mouse model, yet it leads to decreased glucose levels, mirroring outcomes seen in whole-body-inducible Map4k4 knockout animals. Moreover, PF-06260933 administration results in eithe the attenuation of plaque progression or promotion of plaque regression in this model (46.0% versus 25.5%), alongside reductions In both plasma glucose and lipid content.
• In Vitro:
  Treatment with PF-06260933 significantly enhance the resistance of human aortic endothelial cells (EC) to TNF-α-induced increases in endothelial permeability in vitro

Storage & Handling

• Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Disclaimer: For research use only

Alternative Names

Inhibitor, MAPK Kinase Kinase Kinase, MAP4K, MAP4K4 for Cell, MAP4K4 for Kinase, inhibit, PF6260933, PF-6260933, PF06260933, PF-06260933, PF 6260933, PF 06260933

Compound Identifiers

PubChem CID

118701008